- Opinion
- [Reporter’s View] Secrecy no more in pricing negotiations
- by Eo, Yun-Ho Jul 18, 2022 06:06am
- The importance of providing a clear explanation about an administrative decision is essential in the process of handling administrative affairs. This becomes all the more important when an exception arises in the application of a regulation, which raises more questions than an introduction or abolition of a system. But the National Health
- Policy
- Abbott has filed a suspension of execution with the court
- by Kim, Jung-Ju Jul 18, 2022 06:06am
- Abbott Korea, which has been in a dispute with the Ministry of Health and Welfare, immediately filed an appeal against the administrative court ruling by raising the issue of lowering the additional revaluation of the Rytmonorm SR series. Leo Pharma, which raised the issue together last year, decided to avoid legal confrontation with the gove
- Company
- GC WellBeing transfers raw materials technology to Japan
- by Jul 18, 2022 06:06am
- GC Wellbeing (CEO Kim Sang-hyun) announced on the 15th that it has signed a technology transfer contract with Japan's Healthy Navi for the functional raw material Green-Cera F. Healthy Navi is a company in charge of product development and distribution of functional and general food ingredients in Japan. Green-Cera F is a raw material recogni
- Opinion
- [Reporter’s View] Postponing clinical reevaluations by 1 yr
- by Lee, Tak-Sun Jul 18, 2022 06:05am
- The National Health Insurance Service’s Drug Reimbursement Evaluation Committee conducted its first reevaluation to assess the reimbursement adequacy on the anti-inflammatory streptokinase/streptodornase combo and decided that the combination is inadequate for insurance benefit. The drug has been used to ▲relieve acute inflammatory edem
- Company
- SK’s epilepsy drug makes over ₩400 billion in 3 years
- by Chon, Seung-Hyun Jul 15, 2022 05:57am
- SK Biopharmaceuticals’s new anti-epileptic drug ‘Xcopri’ has brought in a total of &8361;400 billion in upfront payments and milestone payments over the past 3 years. This is the largest amount of cash secured by a new drug that was licensed out by Korean pharmaceutical companies. According to the Financial Supervisory Service on the 14th
- Company
- Keytruda adds neoadjuvant/adjuvant therapy indication
- by Jul 15, 2022 05:57am
- MSD’s anti-PD-1 immunotherapy drug ‘Keytruda (pembrolizumab)’ received approval to extend its indication as neoadjuvant/adjuvant therapy in triple-negative breast cancer (TNBC). From the 13th, the Ministry of Food and Drug Safety has extended Keytruda’s indication▲ as neoadjuvant therapy in combination with chemotherapy (carboplatin
- Company
- Daewoong expects sales of 4 new drugs to rise
- by Lee, Tak-Sun Jul 15, 2022 05:57am
- Daewoong Pharmaceutical expects sales to rise through its new drug introduced along with the new drug Fexuclue, a new drug for gastroesophageal reflux disease. This includes biosimilars such as Lexapro, Ogivri, and Alymsys, the No. 1 items in the antidepressant market. According to industries on the 14th, Daewoong Pharmaceutical is plannin
- Company
- EUSA Pharma is entering the Korean market
- by Jul 15, 2022 05:57am
- EUSA Pharma, a British pharmaceutical company specializing in rare diseases, announced its full-fledged entry into the Korean market. EUSA Pharma plans to directly supply the existing domestic approved Castlemans disease treatment, Sylvant (Siltuximab), while also accelerating the introduction of new rare disease treatments. EUSA Pharma held
- Company
- Multinational companies leaving the Korean market
- by Jul 15, 2022 05:57am
- New drugs from multinational pharmaceutical companies such as Otezla, Cotellic, and Erievedge, which were not properly introduced in the domestic market, left the Korean market one after another this year. It is believed that it has made significant sales overseas but has decided to withdraw due to lack of marketability in Korea. According
- Policy
- Samsung reigns over Avastin biosimilar market in Korea
- by Lee, Tak-Sun Jul 14, 2022 05:54am
- No new biosimilars of ‘Avastin (Roche, bevacizumab)' are being introduced to the market after Samsung Bioepis’s biosimilar. The Avastin biosimilar market is estimated to have a &8361;120 billion market in Korea. In terms of approvals, Pfizer Korea and Alvogen Korea had also received approval for their biosimilars after Samsung Bioepis
